DOI QR코드

DOI QR Code

A Case of Minimal Change Disease Treated Successfully with Mycophenolate Mofetil in a Patient with Systemic Lupus Erythematosus

  • Hong, Young-Hoon (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Yun, Dae-Young (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Jung, Yong-Wook (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Oh, Myung-Jin (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Kim, Hyun-Je (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Lee, Choong-Ki (Department of Internal Medicine, Yeungnam University College of Medicine)
  • Published : 2011.12.01

Abstract

The World Health Organization classifies lupus nephritis as class I to V or VI. However, a few cases of minimal change glomerulopathy have been reported in association with systemic lupus erythematosus (SLE). Mycophenolate mofetil has been shown to be effective for treatment of minimal change disease and lupus nephritis. A 24-year-old woman diagnosed with SLE five years prior to presentation complained of a mild generalized edema. The urinalysis showed microscopic hematuria and proteinuria. The assessed amount of total proteinuria was 1,618 mg/24 hours. A renal biopsy demonstrated diffuse fusion of the foot processes of podocytes on electron microscopy. Mycophenolate mofetil was started in addition to the maintenance medications of prednisolone 10 mg/day and hydroxychloroquine 400 mg/day. After six months of treatment, the microscopic hematuria and proteinuria resolved, and the total urine protein decreased to 100 mg/24 hours.

Keywords

References

  1. Churg J, Bernstein J, Glassock RJ. Renal Disease: Classification and Atlas of Glomerular Diseases. 2nd ed. New York: Igaku-Shoin, 1995.
  2. Wang YT, Chou HH, Chen FF, Chen MJ, Chiou YY. A case of minimal-change nephrotic syndrome in pediatric lupus erythematosus: just a coincidence? Lupus 2006;15:244-247. https://doi.org/10.1191/0961203306lu2285cr
  3. Joo HR, An WS, Lee SW, et al. A case of minimal change nephrotic syndrome associated with systemic lupus erythematosus. Korean J Med 2003;65:251-255.
  4. Makino H, Haramoto T, Shikata K, Ogura T, Ota Z. Minimalchange nephritic syndrome associated with systemic lupus erythematosus. Am J Nephrol 1995;15:439-441. https://doi.org/10.1159/000168892
  5. Dube GK, Markowitz GS, Radhakrishnan J, Appel GB, D'Agati VD. Minimal change disease in systemic lupus erythematosus. Clin Nephrol 2002;57:120-126. https://doi.org/10.5414/CNP57120
  6. Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol 2005;16:175-179.
  7. Baglio V, Pecci G, Gangemi C, Barresi G, Morabito S, Pierucci A. Failure of mycophenolate mofetil therapy in primary refractory nephrotic syndrome. J Nephrol 2006;19:819-824.
  8. Zhao M, Chen X, Chen Y, et al. Clinical observations of mycophenolate mofetil therapy in refractory primary nephritic syndrome. Nephrology (Carlton) 2003;8:105-109. https://doi.org/10.1046/j.1440-1797.2003.00146.x
  9. Pesavento TE, Bay WH, Agarwal G, Hernandez RA Jr, Hebert LA. Mycophenolate therapy in frequently relapsing minimal change disease that has failed cyclophosphamide therapy. Am J Kidney Dis 2004;43:e3-e6. https://doi.org/10.1053/S0272-6386(04)00560-8
  10. Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002;61:1098-1114. https://doi.org/10.1046/j.1523-1755.2002.00214.x

Cited by

  1. Reversible Minimal Change Nephrotic Syndrome and Glomerular IgA Deposition Associated with Nonparenteral Heroin Abuse: A Case Report vol.21, pp.5, 2011, https://doi.org/10.1159/000337941
  2. Minimal Change Disease in Systemic Lupus: Another Renal Manifestation of Lupus? vol.36, pp.2, 2011, https://doi.org/10.12771/emj.2013.36.2.139
  3. Acute kidney injury associated with minimal change disease in systemic lupus erythematosus: a case report vol.8, pp.1, 2011, https://doi.org/10.1186/1752-1947-8-422
  4. Prednisolone : Oedema, weight gain, gastrointestinal disturbance and dermatopathy: case report vol.1757, pp.1, 2011, https://doi.org/10.1007/s40278-019-63492-3